Cupid Secures Rs. 16.23 Crore Orders For Male Condoms From Central Medical Services Society

Cupid Limited, a leading manufacturer, has garnered orders totalling Rs. 16.23 crores from the Central Medical Services Society (CMSS) for the supply of male condoms, the company informed in a press statement on Monday. Established as a Central Procurement Agency (CPA) with Cabinet approval, CMSS plays a crucial role in streamlining drug procurement and distribution for the Department of Health & Family Welfare (DoHFW), under the Ministry of Health and Family Welfare, Government of India.

Cupid successfully secured two separate orders for male condoms from CMSS, amounting to Rs. 9.65 crores and Rs. 6.58 crores, respectively. The company aims to fulfil these orders by April 2024, as disclosed in the exchange filing on January 8, 2024.

Aditya Halwasiya, Managing Director of Cupid , expressed excitement about this significant allocation from the Government of India, highlighting the company’s unwavering commitment to supporting the government’s vision of promoting a safe and healthy lifestyle for all citizens. He stated, “This collaboration underscores the importance of ensuring access to vital resources for the well-being of the community at large.”

Furthermore, Halwasiya emphasised Cupid Limited’s alignment with the Government of India’s initiative to “Help India Play Safe.” He mentioned that Cupid Limited’s proposed production capacity expansion in the next 18-24 months positions the company well for future orders from the government.

This development not only strengthens Cupid Limited’s partnership with the Government of India but also reflects the company’s dedication to contributing to public health initiatives. The successful execution of these orders is anticipated to play a vital role in advancing the accessibility of essential resources within the healthcare sector.

Related Posts

Gene Therapy for Cholesterol: Initial Test Results Cheer

Eli Lilly working on single-dose drug to be administered via IV for long-term gain Mumbai: For millions of heart patients struggling with elevated levels of cholesterol, there is a ray…

US Biotech Regeneron to launch Global Capability Centre in Hyderabad

Regeneron Pharmaceuticals, Inc. has announced plans to establish the Regeneron Global Capability Centre (GCC) in Hyderabad, a strategic investment that deepens its global operations and scales business functions to advance…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Gene Therapy for Cholesterol: Initial Test Results Cheer

Gene Therapy for Cholesterol: Initial Test Results Cheer

US Biotech Regeneron to launch Global Capability Centre in Hyderabad

US Biotech Regeneron to launch Global Capability Centre in Hyderabad

Popped the Pill, Paid the Price to Potentially Fatal Skin Syndrome

Popped the Pill, Paid the Price to Potentially Fatal Skin Syndrome

Former Advisor to India’s Union Health Ministry gets Quite a Feather in his Cap

Former Advisor to India’s Union Health Ministry gets Quite a Feather in his Cap

Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

STF busts fake meds racket spread across 6 states

STF busts fake meds racket spread across 6 states